Abstracts tagged "Disease Activity"

Abstract Number: 692 • 2017 ACR/ARHP Annual Meeting
High Plasma Factor XIII Transglutaminase Activity Inversely Correlates with SLE Disease Activity Yet Associates with Higher Carotid Artery IMT and Low CD14+CD16+ Monocyte Levels
Brian Skaggs¹, Isao Matsuura², Elaine Lourenco¹, Eloise Olmos³, Jennifer M. Grossman¹ and Maureen A. McMahon¹, ¹University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ²Department of Rheumatology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan, ³Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: The transglutaminase Factor XIII (FXIII) stabilizes blood clots through crosslinking fibrin lysine and glutamine residues at the end of the complement cascade. Enzymatic activity…
Abstract Number: 1232 • 2017 ACR/ARHP Annual Meeting
The Perceived Impact of Recent-Onset Psoriatic Arthritis Is Different between Genders: A Spanish Multicenter Experience
Rubén Queiro¹, Ana Laiz², Carlos Alberto Montilla-Morales³, Eva Galindez-Agirregoikoa⁴, Juan J. Bethencourt⁵ and Daniel Seoane⁶, ¹Rheumatology Department. Hospital Universitario Central de Asturias, Oviedo, Spain, ²Rheumatology, HU. Santa Creu i San Pau, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca, Salamanca, Spain, ⁴Rheumatology Division, Hospital Universitario de Basurto, Bilbao, Spain, ⁵Rheumatology, HU. Canarias, Sta. Cruz de Tenerife, Spain, ⁶Research Unit, Spanish Foundation of Rheumatology, Madrid, Spain
Background/Purpose: Some studies point to a differential clinical expression between men and women with PsA, but the information on gender differences is very scarce in…
Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Bente Glintborg¹, Ulf Lindström², Kalle Aaltonen³, Eirik K Kristianslund⁴, Björn Gudbjornsson⁵, Katerina Chatzidionysiou², Johan Askling⁶, Dan Nordström⁷, Merete Lund Hetland⁸, Daniela Di Giuseppe⁹, Lene Dreyer¹⁰, Tanja Schjødt Jørgensen¹¹, Lars Erik Kristensen¹⁰, Kari Eklund³, Gerdur Grondal¹², Sofia Ernestam², Jaana Joensuu³, Tore K Kvien¹³, Elisabeth Lie¹³, Karen M Fagerli¹³, Arni Jon Geirsson¹², Helgi Jonsson¹² and Lennart TH Jacobsson¹⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, ³On behalf of the ROB-FIN registry, Helsinki, Finland, ⁴Dept. of Rheumatology, On behalf of the NOR-DMARD registry, Oslo, Norway, ⁵ICEBIO, Reykjavik, Iceland, Reykjavik, Iceland, ⁶Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁷ROB-FIN, Helsinki, Finland, Helsinki, Finland, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰On behalf of the DANBIO registry, Copenhagen, Denmark, ¹¹On behalf of the DANBIO registry, Copenhagen F, Denmark, ¹²On behalf of the ICEBIO registry, Reykjavik, Iceland, ¹³On behalf of the NOR-DMARD registry, Oslo, Norway, ¹⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 2336 • 2017 ACR/ARHP Annual Meeting
Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis
Sirisucha Soponkanaporn¹, Claire Deakin², Lucy Marshall², Cerise Johnson², Peter Schutz¹ and Lucy R Wedderburn², ¹Infection Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, ²Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic autoimmune myopathy characterized by proximal muscle weakness and typical skin rashes. Type I interferon (IFN) gene expression in…
Abstract Number: 2534 • 2017 ACR/ARHP Annual Meeting
the Relationship between Biological Therapy, Work Productivity, and Activity Impairment in Patients with Psoriatic Arthritis: Prospective Multicentre Observational Study
Jiri Stolfa¹, Tomas Mlcoch², Jan Tuzil², Liliana Sedova³, Jitka Jircikova⁴, Monika Gregova⁵, Tomas Dolezal⁴ and Karel Pavelka⁶, ¹Instituite of Rheumatology Prague, Rheumatology, Prague, Czech Republic, ²Institute of Health Economics and Technology Assessment (iHETA), Statistician, Prague, Czech Republic, ³Institute of Rheumatology Prague, rheumatologist, Prague, Czech Republic, ⁴Institute of Health Economics and Technology Assessment (iHETA), statistician, Prague, Czech Republic, ⁵Instituite of Rheumatology Prague, rheumatologist, Prague, Czech Republic, ⁶Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Psoriatic arthritis (PsA) is a progressive disease bringing substantial socioeconomic burden. Gradual loss of productivity (PL) and daily activities can be modified by effective…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…
Abstract Number: 144 • 2017 ACR/ARHP Annual Meeting
Are RA Patients at a Higher Risk for Car Accidents?
Kaleb Michaud^1,2, Sofia Pedro¹ and Ted R. Mikuls³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Automobile driving is an important instrumental activity of daily living with heightened importance among arthritis sufferers who are disproportionately reliant on driving for the…
Abstract Number: 694 • 2017 ACR/ARHP Annual Meeting
Serum Wisteria Floribunda Agglutinin-Positive Mac-2-Binding Protein Can Reflect Systemic Lupus Erythematosus Activity
Sung Soo Ahn¹, Younhee Park², Seung Min Jung¹, Jason Jungsik Song¹, Yong-Beom Park¹ and Sang-Won Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of (South)
Abstract Background/Purpose : Serum Mac-2-binding protein (M2BP) is elevated in various chronic inflammatory diseases. Recently, the Wisteria floribunda agglutinin positive-M2BP (WFA+-M2BP) immunoassay has shown promise…
Abstract Number: 1238 • 2017 ACR/ARHP Annual Meeting
The Development of the Lupus Foundation of America—Rapid Evaluation of Activity in Lupus (LFA-REAL™) Patient-Reported Outcome (PRO) to Evaluate Lupus Disease Activity
Anca Askanase¹, Samantha Nguyen², Miya Okado², Nancy Leidy³ and Joan T. Merrill⁴, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ³Evidera, Bethesda, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The LFA REALTM is designed as two complimentary disease activity measures in order to integrate clinician and patient input. The current report updates progress…
Abstract Number: 1549 • 2017 ACR/ARHP Annual Meeting
A Non-Medical Switch from Originator Infliximab to Biosimilar CT-P13 in 36 Patients with Ankylosing Spondylitis: 6 – Months Clinical Outcomes from the Czech Biologic Registry Attra
Šárka Forejtová¹, Jakub Zavada¹, Lenka Szczukova², Katerina Jarosova¹, Tom Philipp³ and Karel Pavelka⁴, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Czech Republic, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Brno, Czech Republic, ³Department of Rheumatology and Physiotherapy, Thomayer Hospital, Prague, Praha 4, Czech Republic, ⁴Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: A non-medical switch from originator (INX, Remicade) to biosimilar infliximab (CT-P13, Remsima) was conducted in 36 patients with ankylosing spondylitis (AS) in one clinical…
Abstract Number: 1847 • 2017 ACR/ARHP Annual Meeting
The IgG4:IgG RNA Ratio in Peripheral Blood Perfectly Differentiates Active Disease from Remission in Granulomatosis with Polyangiitis. a New Disease Activity Marker?
Aram Al-Soudi^1,2,3, Marieke E. Doorenspleet⁴, Rebecca Esveldt⁵, Lot Burgemeister⁵, Liesbeth Hak⁵, Sander W. Tas⁶, Ronald F van Vollenhoven⁷, Paul L. Klarenbeek^5,8 and Niek de Vries^5,9, ¹Dept of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands, ²Dept of Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Dept of Genome Analysis, Academic Medical Center, Amsterdam, Netherlands, ⁴ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Clinical Immunology & Rheumatology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁶Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, ARC | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁷Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁸Dept. of Experimental Immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁹Laboratory of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is characterized by vasculitis in lungs, kidneys and the ear, nose and throat region. Regular monitoring and treatment adjustments are…
Abstract Number: 2346 • 2017 ACR/ARHP Annual Meeting
Chemokine Ligand 9 (CXCL9) [Monokine Induced By Gamma Interferon (MIG)] As a Predictor of Active Disease Status in Localized Scleroderma
Kathryn S. Torok¹, Qi Mi², Emily Mirizio³, Kaila Schollaert-Fitch¹, Mark Fritzler⁴ and Marvin J. Fritzler⁵, ¹Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ²Department of Sports Medicine and Nutrition, University of Pittsburgh, Pittsburgh, PA, ³Pediatric Rhuematology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Eve Technologies, Calgary, AB, Canada, ⁵Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Localized scleroderma (LS) is a fibrotic autoimmune disease of the skin and underlying tissues which can lead to disfiguring sequlea, especially in childhood-onset. Untreated…
Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Maria Laura Acosta Felquer¹, Musaab Elmamoun², Agnes Szentpetery^3,4, Phil Gallagher⁵, Oliver FitzGerald⁶ and Enrique R. Soriano⁷, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Rheumatology, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁴Bone & Joint Unit, Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ⁵St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁶St. Vincent's University Hospital, Department of Rheumatology. UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland, ⁷Rheumatology Unit, Internal Mecine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…
Abstract Number: 2917 • 2017 ACR/ARHP Annual Meeting
Neutrophil Activation in Rheumatoid Arthritis – Potential Biomarkers of Disease Activity and Severity
Mary Bach¹, Daniel Moon², Marcel Bach², Marcus Bach² and Christian Lood³, ¹VA Puget Sound Health Care System, Seattle, WA, ²University of Washington, Seattle, WA, ³Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation is associated with inflammation and autoimmunity, including rheumatoid arthritis (RA), where neutrophil infiltration to joints participates in tissue destruction and development of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].